NDA 020193 · Janssen Pharms
Elmiron
Pentosan Polysulfate Sodium · Oral
NovelOrphanLast checked: Nov 19, 2026Latest source record: Mar 12, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Sep 26, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
5 Phase 3, 2 recruiting
FAERS reports
6,930
4,861 serious, 120 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 18, 2024.
INDICATIONS AND USAGE ELMIRON ® (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 26, 1996 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
- ELMIRON · PENTOSAN POLYSULFATE SODIUM 100MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pentosan Polysulfate" as an intervention, any sponsor and status, largest first.
- Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA PainPivotal-lookingActive, not recruiting
Paradigm Biopharmaceuticals USA (INC)Industry
NCT04809376 · 602 participants · Start Oct 19, 2021 · Primary completion Oct 15, 2024
Drug: Pentosan Polysulfate Sodium twice weekly; Placebo (Sodium Chloride Injection, 0.9%) and 2 more · For: Osteoarthritis, Knee
Sites: Tempe, Arizona; Tucson, Arizona; Cerritos, California · 33 sites in all
- A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.Pivotal-lookingActive, not recruiting
Paradigm Biopharmaceuticals Ltd.Industry
NCT06917404 · 466 participants (planned) · Start May 29, 2025 · Primary completion Jul 2027
Drug: Pentosan Polysulfate Sodium twice weekly; Placebo · For: Osteoarthritis, Knee
Sites: Peoria, Arizona; Tucson, Arizona; Anaheim, California · 57 sites in all
- Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial CystitisPivotal-lookingTerminated
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00086684 · 369 participants · Start Sep 2003 · Primary completion Jun 2011
Drug: Pentosan polysulfate sodium 100 mg; Placebo and 1 more · For: Interstitial Cystitis
Sites: Birmingham, Alabama; Homewood, Alabama; Anchorage, Alaska · 65 sites in all
- Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in WomenPivotal-lookingRecruiting
TCM Biotech International Corp.Industry
NCT07184827 · 348 participants (planned) · Start Oct 14, 2020 · Primary completion Jun 30, 2028
Drug: U101 · For: Recurrent Urinary Tract Infections in Women
Sites: Chiayi City, Taiwan; Douliu, Taiwan; Kaohsiung City, Taiwan · 18 sites in all
- An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate GlandPivotal-lookingCompleted
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Industry
NCT00236990 · 283 participants
Drug: pentosan polysulfate sodium · For: Prostatitis
- Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation TherapyPivotal-lookingCompleted
Radiation Therapy Oncology GroupResearch network
NCT00003825 · 174 participants (planned) · Start Jun 1999 · Primary completion Apr 2006
Drug: pentosan polysulfate sodium · For: Diarrhea; Radiation Enteritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 260 sites in all
- Radiation Cystitis Treated With Pentosan Polysulfate Sodium TrialPivotal-lookingRecruiting
National Taiwan University HospitalAcademic, hospital or other
NCT05245591 · 72 participants (planned) · Start Apr 29, 2022 · Primary completion Nov 1, 2024
Drug: Pentosan Polysulfate Sodium 100 MG Oral Capsule; Placebo · For: Radiation Cystitis
Sites: Taipei, Taiwan
- Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic DisordersCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT02930005 · 8 participants · Start Aug 7, 2015 · Primary completion Oct 6, 2016
Drug: Meclofenamic acid; Pentosan polysulfate sodium · For: Psychotic Disorders; Schizophrenia; Schizoaffective Disorder and 1 more
Sites: Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,404
- maculopathy1,398
- retinal pigmentation607
- dry age-related macular degeneration562
- pigmentary maculopathy470
- drug ineffective354
- pain304
- nausea278
- product use issue272
- headache237
- cystitis interstitial214
- macular degeneration214
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 51 |
| 2006 | 57 |
| 2007 | 52 |
| 2008 | 69 |
| 2009 | 70 |
| 2010 | 112 |
| 2011 | 169 |
| 2012 | 157 |
| 2013 | 146 |
| 2014 | 170 |
| 2015 | 565 |
| 2016 | 355 |
| 2017 | 276 |
| 2018 | 331 |
| 2019 | 334 |
| 2020 | 499 |
| 2021 | 686 |
| 2022 | 1,541 |
| 2023 | 601 |
| 2024 | 331 |
| 2025 | 223 |
| 2026 | 94 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Elmiron (Pentosan Polysulfate Sodium)
2024 spending
$52.0M
Beneficiaries
9,098
42,953 claims
Per beneficiary
$5,711
$11.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $83,470,502 |
| 2021 | $63,370,871 |
| 2022 | $58,415,643 |
| 2023 | $55,269,822 |
| 2024 | $51,962,064 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome.
Clemens JQ, Erickson DR, Varela NP, et al. · J Urol 2022 · Systematic Review
- Chronic prostatitis.
Le B, Schaeffer AJ · BMJ Clin Evid 2011 · Systematic Review
- Chronic prostatitis.
Erickson BA, Schaeffer AJ, Van Le B · BMJ Clin Evid 2008 · Systematic Review
- Risk and Dose-Response Relationship for Pentosan Polysulfate Sodium Maculopathy: A Systematic Review and Meta-Analysis.
Tao BK, Sawires K, Lim K, et al. · Ophthalmol Retina 2025 · Systematic Review, Meta-Analysis
- Pentosan Polysulfate Maculopathy: What Urologists Should Know in 2020.
Paredes Mogica JA, De EJB · Urology 2021 · Systematic Review
- Efficacy of different treatment strategies in patients with mucopolysaccharidosis: a systematic review and network meta-analysis of randomized controlled trials.
Huang L, Wu J, Tang B, et al. · Orphanet J Rare Dis 2025 · Network Meta-Analysis, Systematic Review
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.